Ian Bezek

Ian Bezek

Ian Bezek earned his economics degree from Colorado State University in 2010. He then worked as an analyst for Kerrisdale Capital, a New York City-based activist hedge fund, from 2011-13. Since then, Ian has focused on finding under-the-radar investment opportunities, particularly overseas. To that end, he taught himself Spanish and has lived in Mexico and Argentina among other countries. He currently resides in Colombia with his family.

You can interact with Ian on Twitter.

Recent Articles

Wait for a Correction to Buy Snap Stock

How are things looking for Snap stock in 2020, and what will the company's recent AI Factory acquisition add to the mix?

It’s Not Time to Abandon General Electric Stock Yet

General Electric is set to report earnings later this month. Here's why GE stock can continue to rally into that report.

Who Won: Intel and AMD Face Off at CES 2020

AMD is doubling down on its currently-successful strategy, while Intel is planning for the long-term. Which will deliver more shareholder value?

7 Healthcare Stocks to Buy or Sell As Pricing Pressures Mount

Politicians have investors in healthcare stocks nervous as the 2020 election nears. Here's a guide to which firms are good choices and which you should avoid.

4 Vaping Stocks to Consider Buying Now

Investors are dumping their vaping stocks as public outcry and regulatory risk are mounting. However, this selloff created some solid buys.

Where Does Technical Communications Stock Go After Its 150% Gain?

Technical Communication has sprung back to life in recent weeks. Will the tense situation with Iran be able to lift the price of TCCO further?

Don’t Buy Chesapeake Energy Stock on Iran War Fears

CHK stock wouldn't necessarily jump if a war breaks out, and the company's fiscal situation is currently dire.

Nio Won Its Latest Battle, but It’s Still Losing the War

The market is acting as if Nio delivered an excellent earnings report. But, in truth, it left investors with plenty of troubling questions.

Underperforming Pinterest Stock Should Surge in 2020

Although Pinterest stock eventually disappointed after its IPO demonstrated early promise, patient investors willing to see the narrative play out may be rewarded handsomely.

Here’s Why Amarin Stock Slumped Despite the FDA Approval

Although the FDA approval is nice, fundamentally, Amarin stock is banking on a fish oil drug. Given its similarity to OTC counterparts, that doesn’t bode well for stakeholders.